Dr Boomi’s Contributions (Res)

The Founder President & Director-cum-chief-Scientist, Dr. L. Boominathan’s Research contributions & their Significance

1. Dr Boominathan was the first one to propose a p73/p63-dependent tumor suppressor pathway:

The p53 gene was initially thought to function as an Oncogene.  It took more than ten years to establish that p53 is a tumor suppressor gene.  Similarly, it was not clear whether p53 homologue p63/p73 could function as a tumor suppressor gene.  Dr Boominathan has proposed for the first time that p63/p73, by transactivating the myeloid leukemia (CML)/B-cell tumor suppressor JunB, it could increase the expression of the tumor suppressor INK4a/BRCA1 {as JunB is an activator of INK4a/BRCA1 [Boominathan, Invention disclosure 2002; Molecular cancer, 2007] }, thereby functioning as a tumor suppressor gene.

Further, Dr Boominathan has proposed for the first time that p63 could increase the expression of the tumor suppressor AML-1, which in turn could increase the expression of the tumor suppressor p14ARF/INK4a (Boominathan, Invention disclosure 2003).  Increased expression of p14ARF/INK4a has been shown to promote senescence—a tumor suppressor mechanism—in a number of cell types, indicating that the p73/p63-AML-1/JunB-p14ARF/INK4a/BRCA pathway could promote tumor suppression in a cell context-dependent manner (Boominathan, Invention disclosure 2003; & Cancer & Metastasis rev, 2010).

This is to emphasize that Dr Boominathan had the insight for the first time [Inventor: Boominathan, Invention disclosure 2002/2003] that p73 and p63 could function as tumor suppressors and the mechanism through which they function as tumor suppressors.

2. Dr Boominathan was the first one to (i) coin the term “tumorsuppressome”; (ii) propose DNp63 could function as a guardian of Epithelial integrity; (iii) propose p63 could function as a Guardian of Human Heart; Guardian of Longevity; & Fecilitator of Regeneration (iv) propose that p53 family members TA-p73 and p63 could also be considered as “Guardians of the genome & the Guardians of Gerosuppression”; (v)  propose that p63/p73/p53 functions as a Sentinel of autoimmune inflammation; (vi) conceptualize and reduce it to practice the ability of p73 to increase AP-1 activity in co-operation with the c-Jun (This work is an integral part of Dr Boominathan’s Ph.D. thesis; and the paper published in a premier journal namely Nature cell biology (2007).  Ph.D.  thesis can be found at http://scholarbank.nus.edu.sg/handle/10635/15006 (2005) .

3. Dr Boominathan was the first one to show that: (i)  c-Jun could increase p73 levels (this work has led the group leader to obtain an International patent –http://www.google.com/patents/US20060127895?printsec=description&dq=Jun+p73&ei=bPXmT5jJOszIrQfc2ZT5CA#v=onepage&q=Jun%20p73&f=false–worth of 1 billion american dollars/year.  To quote their own words, “The potential market for such a drug could easily be in excess of US$ ONE billion/year.” Reference :  The Market value of Patent applied during Dr Boominathan’s tenure at NCC Singapore. Refer posters 1 to 5 under conference publications to ascertain Dr Boominathan’s contributions); (ii) UV could increase p73 levels; (iii) p73 could function like an oncogene (or supports growth) in the presence of excessive oncogenic signals; (iv) both TA-p63 and DN-p63 could increase DNA synthesis; (v) p63 is required for S-phase entry in immortalized cells; (vi) p53-miRs target the miRNA processing components;  and (vii) p63/p73 could play a role in miRNA processing (Boominathan,The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex, May, 2010, Plos One).   It was a single-authored research paper; and the most down loaded article of the year 2010-2011 in the field of miRNAs.  Evidently, the data presented in this study was found to be reproduced recently in top-notch journals in bio-medical sciences, such as Cell (Martello et al., Jun 25, 2010); Nature (Xu et al., Oct 21, 2010); and J Clin Invest (Ory et al.,   Jan 10, 2011).

4. Dr Boominathan  has published an article—The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network; more of a research perspective than a review article— in Cancer & Metastasis rev (Impact factor: 10.573).  It was a single-authored paper.  It was the most downloaded article of the years from 2010 to 2013. Furthermore, the data discussed in this study was found to be reproduced recently in JAMA (Impact factor: 28.89; Fabbri et al., 2011 Jan 5;305(1):59-67); and The EMBO Journal (Impact factor: 8.993; Ugalde et al., Apr 26 2011).

5. The data presented in another study (Boominathan,p63, p73, & p53 are negative regulators of epithelial to mesenchymal transition (EMT), invasion & metastasis, Nature precedings, 2009) was reproduced recently in premier journals such as Nature cell biology (Chang et al., 20 Feb 2011),  J Exp Med.  (Impact factor: 15.46; Kim et al., Apr 2011) ); Cell Death Differ. (Impact factor: 8.24; Magenta et al., Apr 2011); and Cell Research (Impact factor: 8.151; Schubert, Apr 2011)

6. Dr Boominathan had filed an international patent namely “Therapeutic uses of miRNAs/compounds that activate tumor suppressor genes/miRNAs network in 2010.  It has recently been published by the international patent office, Geneva (WIPO), Switzerland.  Dr Boominathan is the sole inventor named in the patent application published.

Reference nos.: 2505/CHE/2010 (India); PCT/IN2011/000684 (International)

The patent can be accessed here:

http://patentscope.wipo.int/search/en/WO2012073253

7. Dr Boominathan has more than 15  Invention disclosures (from 2006 to 2011) to his credit.

8. Dr L Boominathan has published 7000+ Bio-medical/pharma/therapeutic/clinical ideas (as of March/2015) related to Cancer, Cardiovascular disease (myocardial infarction, cardiomyopathy, cardiachypertrophy), diabetes, hypertension, ageing, regenerative medicine, longevity, healthspan, neurodegenerative diseases, bone related disorders etc.,  a credit shared by no other bio-scientist in the world.